A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

Research output: Contribution to journalArticlepeer-review


  • Rohit Lal
  • James Dickson
  • David Cunningham
  • Ian Chau
  • Andrew R Norman
  • Paul J Ross
  • Clare Topham
  • Mark Hill
  • Jacqui Oates

Colleges, School and Institutes


Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.


Original languageEnglish
Pages (from-to)3023-31
Number of pages9
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 2004